CompletedPHASE1, PHASE2NCT01534585

Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma

Studying Nasopharyngeal carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Taizhou Hospital
Principal Investigator
Haihua Yang, MD.
Department of Radiation Oncology, Taizhou Hospital, Wenzhou Medical College.
Intervention
Icotinib(drug)
Enrollment
48 target
Eligibility
18-70 years · All sexes
Timeline
20122015

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01534585 on ClinicalTrials.gov

Other trials for Nasopharyngeal carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Nasopharyngeal carcinoma

← Back to all trials